Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 6/20 | 0.49 |
| ▸ | BCL2 | P10415 | 7/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19183275 | 0.88 | PTGS2 (0.44) | BCL2L1BCL2PTGS2PTGS1SLC6A3 | |
| SCHEMBL25215204 | 0.87 | BCL2L1 (0.51) | BCL2L1BCL2PTGS2PTGS1PTGES | |
| SCHEMBL10058349 | 0.86 | BCL2L1 (0.50) | BCL2L1BCL2PTGS2PTGS1PTGES | |
| SCHEMBL1113744 | 0.84 | BCL2L1 (0.52) | BCL2L1BCL2PTGS2PTGS1PTGES | |
| SCHEMBL18011819 | 0.84 | BCL2L1 (0.49) | BCL2L1BCL2PTGS2PTGS1PTGES | |
| SCHEMBL19145307 | 0.82 | BCL2L1 (0.46) | BCL2L1BCL2PTGS2PTGS1 | |
| SCHEMBL22566773 | 0.77 | BCL2L1 (0.44) | BCL2L1BCL2PTGS2PTGS1SLC6A3 | |
| SCHEMBL19014652 | 0.77 | PTGS2 (0.45) | BCL2L1BCL2PTGS2PTGS1SLC6A3 | |
| SCHEMBL15826881 | 0.76 | BCL2L1 (0.65) | BCL2L1BCL2 | |
| SCHEMBL1959392 | 0.76 | PTGS2 (0.45) | BCL2L1BCL2PTGS2PTGS1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024067818-A1 | CHIMERIC COMPOUND USED FOR TARGETED DEGRADATION OF BCL-2 PROTEIN, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | 江苏恒瑞医药股份有限公司 | 2024-04-04 | — | — | WO | disclosed |
| US-11111259-B2 | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders | UNITY BIOTECHNOLOGY, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20200291050-A1 | ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS | UNITY BIOTECHNOLOGY, INC. | 2020-09-17 | — | — | US | disclosed |
| WO-2017101851-A1 | ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS | UNITY BIOTECHNOLOGY, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| EP-2094672-B1 | ARYLSULFONAMIDE COMPOUNDS | GENENTECH INC (US) | 2013-05-29 | — | — | EP | disclosed |
| EP-2094672-B1 | ARYLSULFONAMIDE COMPOUNDS | GENENTECH INC (US) | 2013-05-29 | — | — | EP | disclosed |
| US-8168645-B2 | Arylsulfonamide compounds | GENENTECH, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168645-B2 | Arylsulfonamide compounds | GENENTECH, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168645-B2 | Arylsulfonamide compounds | GENENTECH, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAELL JONATHAN BAYLDON | 2011-04-28 | — | — | US | disclosed |
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAELL JONATHAN BAYLDON | 2011-04-28 | — | — | US | disclosed |
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAELL JONATHAN BAYLDON | 2011-04-28 | — | — | US | disclosed |
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| WO-2009143246-A2 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| EP-2094672-A2 | ARYLSULFONAMIDE COMPOUNDS | Genentech, Inc. (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008061208-A2 | ARYLSULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | BCL2A1, BCL2, BAX | BCL2L1 5/4885BCL2 2/4885PTGS2 1737/4885 |
| US-11111259-B2 | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders | ACAT1, ARSA, GLA | BCL2L1 3463/4885BCL2 3060/4885PTGS2 2272/4885 |
| US-20200291050-A1 | ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS | ACAT1, ARSA, GLA | BCL2L1 3463/4885BCL2 3060/4885PTGS2 2272/4885 |
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAX, API5, BCL2 | BCL2L1 13/4885BCL2 3/4885PTGS2 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.